Drug Profile
Research programme: prostate cancer therapeutic - Access Pharmaceuticals
Latest Information Update: 14 Jun 2014
Price :
$50
*
At a glance
- Originator Access Pharmaceuticals; Unknown
- Developer Access Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 14 Jun 2014 No development reported for Prostate cancer in USA (PO)
- 27 Oct 2010 Early research in Prostate cancer in USA (PO)